Results 31 to 40 of about 66,826 (280)

Disease activity and cognition in rheumatoid arthritis : an open label pilot study [PDF]

, 2012
Acknowledgements This work was supported in part by NIHR Newcastle Biomedical Research Centre. Funding for this study was provided by Abbott Laboratories.
Birchall, Daniel, Blamire, Andrew M, He, Jiabao, Isaacs, John D, Newton, Julia L, Pearce, Ruth, Raftery, Graham   +6 more
core   +1 more source

Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial

Trials, 2020
Background Juvenile idiopathic arthritis (JIA)-associated uveitis is a chronic paediatric ocular inflammatory condition that can result in visual impairment.
Nisha R. Acharya, Caleb D. Ebert, Nicole K. Kelly, Travis C. Porco, Athimalaipet V. Ramanan, Benjamin F. Arnold, the ADJUST Research Group   +6 more
doaj   +1 more source

The risk of tuberculosis infection in 410 Saudipatients receiving adalimumab therapy

Annals of Saudi Medicine, 2021
BACKGROUND: Adalimumab is a fully humanized monoclonal antibody inhibitor of tumor necrosis factor-a used to treat various autoimmune disorders. Adalimumab poses a risk for tuberculosis (TB) infection, especially in countries where TB is endemic ...
Abdullah Al-Sohaim, Abdullah Saleh Bawazir, Turki Al-Turki, Eiman Omar Alsafi, Abdullah Al-Roqy, Layla Layqah, Salim Alawi Baharoone   +6 more
doaj   +1 more source

Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment

Pediatric Rheumatology Online Journal, 2023
Background Adalimumab is currently considered the most efficacious anti-TNFα agent for childhood noninfectious uveitis (NIU). The objective of this study was to define a therapeutic range for adalimumab trough levels in the treatment of childhood NIU ...
Jo L. Dehoorne, Helena Groth, Emma Carlé, Ilse De Schrijver, Celine Sys, Patricia Delbeke, Elke O. Kreps, Thomas Renson, Carolien Bonroy   +8 more
doaj   +1 more source

TCD4pos lymphocytosis in rheumatoid and psoriatic arthritis patients following TNFα blocking agents [PDF]

, 2017
BACKGROUND: Lymphocyte expansion and true lymphocytosis are commonly observed in the everyday clinical practice. The meaning of such phenomenon is often poorly understood so that discrimination between benign and malignant lymphocytosis remains ...
Amodeo, Rachele, Bove, Maurizio, Cox, Maria Christina, D'Amelio, Raffaele, DI ROSA, Roberta, Lagana', Bruno, Markovic, Milica, PICCHIANTI DIAMANTI, Andrea, Pilozzi, Emanuela, Rosado, Maria Manuela, Salemi, Simonetta, Sorgi, Maria Laura   +11 more
core   +1 more source

Adalimumab Monotherapy in the Treatment of Idiopathic Multifocal Choroiditis: A Case Report

Case Reports in Ophthalmology, 2022
In this study, we report a case of multifocal choroiditis that was successfully treated with adalimumab monotherapy. A 25-year-old male presented with a history of bilateral multifocal choroiditis which was resistant to a combination of azathioprine ...
Arash Maleki, Andrew Philip, C. Stephen Foster   +2 more
doaj   +1 more source

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study

Pharmacology Research & Perspectives, 2021
The primary objective of this randomized, double‐blind, parallel‐controlled study (from December 2016 to October 2018) was to evaluate pharmacokinetic (PK) equivalence of adalimumab biosimilar HLX03 and reference adalimumab in healthy volunteers, and to ...
Hong Zhang, Min Wu, Jixuan Sun, Xiaoxue Zhu, Cuiyun Li, Yanhua Ding, Xiaodi Zhang, Katherine Chai, Xiaojiao Li   +8 more
doaj   +1 more source

Persistencia de medicamentos biológicos durante ocho años en pacientes con artritis reumatoide y espondiloartritis [PDF]

, 2019
Objective: To calculate the persistence, over a period of eight years, the retention rate of first and second-line of treatment with biological agents in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis and to compare ...
Balsa, Alejandro, González-Fernández, María, Herrero, Alicia, Jiménez-Nácher, Inmaculada, Moreno, Francisco, Villamañán, Elena   +5 more
core   +3 more sources

A Rare Side Effect due to TNF-Alpha Blocking Agent: Acute Pleuropericarditis with Adalimumab

Case Reports in Rheumatology, 2013
Tumor necrosis factor-alpha antagonism is an important treatment strategy in patients with rheumatoid arthritis, psoriatic arthritis, vasculitis, and ankylosing spondylitis. Adalimumab is one of the well-known tumor necrosis factor-alpha blocking agents.
Hakan Ozkan, Ahmet Seckin Cetinkaya, Tekin Yildiz, Tahsin Bozat   +3 more
doaj   +1 more source

Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis [PDF]

, 2015
Objective. To evaluate the efficacy and safety of adalimumab in patients with active nonpsoriatic peripheral spondyloarthritis (SpA). Methods. ABILITY-2 is an ongoing phase III, multicenter study of adalimumab treatment.
Karunaratne, P Mahinda, Mease, Philip, Pangan, Aileen L, Rahman, Proton, Sieper, Joachim, Van den Bosch, Filip   +5 more
core   +1 more source